Antimicrobial compositions and methods for depositing or coating the antimicrobial or antibacterial compositions on a substrate to prevent microbial adhesion are provided. The antimicrobial composition may include a cationic polymer having a poly-allylamine backbone. A portion of the poly-allylamine backbone may be functionalized with at least one of a guanidine functional group and a biguanide functional group.

Antimicrobial compositions and methods for depositing or coating the antimicrobial or antibacterial compositions on a substrate to prevent microbial adhesion are provided. The antimicrobial composition may include a cationic polymer having a poly-allylamine backbone. A portion of the poly-allylamine backbone may be functionalized with at least one of a guanidine functional group and a biguanide functional group.

Disclosed are hydrophobic, acrylic materials having both high refractive index and a high Abbe number. The materials may have an internal wetting agent, are well suited for use as implantable ophthalmic devices, and have a refractive index which may be edited through application of energy. When used for an intraocular lens, the high refractive index allows for a thin lens which compresses to allow a small incision size.

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is SO.sub.3.sup. or H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is SO.sub.3.sup. or H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is SO.sub.3.sup. or H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

This invention relates to a process for forming a long-chain branched polymer and a long-chain branched polymer resulting from the process. The process comprises reacting (a) a polyolefin base polymer with (b) a coupling agent comprising a polymeric coupling agent, optionally blended with a molecular coupling agent, the polymeric coupling agent being a modified polyolefin having a reactive coupling group at one or more terminal ends of the modified polyolefin chain, to couple the polyolefin base polymer (a) with the coupling agent (b) to form a long-chain branched polymer having a long-chain branching and/or higher surface energy relative to the polyolefin base polymer.

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is SO.sub.3.sup. or H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is SO.sub.3.sup. or H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is SO.sub.3.sup. or H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.